FDA puts 2seventy CAR-T trial on hold in wake of patient death

The FDA has put an early-phase trial of 2seventy bio’s CD33-targeted CAR-T cell therapy on hold in the wake of a patient death. The trial’s investigators had already paused the trial in June following news that an acute myeloid leukemia patient, the first person treated by Seattle Children’s in the second dose cohort of the phase 1 study, had died.